Clinical Significance of Platelet Recovery During Revumenib (Menin Inhibitor) Therapy

　　1.Impact on Platelet Dynamics

　　Revumenib is a selective menin-KMT2A inhibitor approved for KMT2A-rearranged acute leukemias.These malignancies often present with thrombocytopenia due to bone marrow failure.During initial treatment,patients may experience a further drop in platelets(treatment-related cytopenia)as the drug targets leukemic clones.This nadir typically occurs at weeks 2-3,followed by a gradual recovery as normal hematopoiesis resumes.

　　2.Prognostic Value of Normalization at 2 Months

　　Achieving a normal platelet count(>100×10^9/L)after two months of therapy is a highly positive indicator,suggesting:

　　Effective clearance of leukemic cells and restored bone marrow function.

　　Absence of irreversible drug-induced bone marrow toxicity.

　　Potential achievement of Complete Remission(CR)or CR with incomplete blood count recovery(CRi).

　　Note:Confirmation requires bone marrow biopsy showing blasts<5%.

　　3.Efficacy Assessment Timeline

　　Efficacy is formally assessed at Day 28 and Day 56.A platelet count>100×10^9/L and blasts<5%at Day 56 confirms CR.While platelet recovery is a key milestone,clinicians must also evaluate neutrophil and hemoglobin recovery.

　　4.Long-term Monitoring

　　Continue Revumenib for at least 6 cycles or until disease progression,even if platelets normalize.Monitor Measurable Residual Disease(MRD)every 3 months.A subsequent drop in platelets warrants investigation for relapse or immune-mediated thrombocytopenia.

　　5.Considerations and Economic Factors

　　Normal platelets do not equate to a cure;regular follow-up is essential.If platelets recover but blasts persist(Partial Remission),combination therapy(e.g.,Venetoclax or chemotherapy)may be needed.The overseas cost is substantial(approx.$850-$1150 per box);however,continuing therapy during response is critical for outcomes.